Welcome to our dedicated page for Atricure news (Ticker: ATRC), a resource for investors and traders seeking the latest updates and insights on Atricure stock.
AtriCure, Inc. (Nasdaq: ATRC) is a medical device company focused on surgical treatments and technologies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management. The ATRC news page on Stock Titan aggregates company announcements, clinical milestones, product updates, and financial disclosures that shape the outlook for this Afib and surgical pain management specialist.
Investors and healthcare professionals following AtriCure can use this feed to monitor earnings releases and financial guidance, which the company regularly reports via Form 8-K and press releases. Recent updates have included preliminary quarterly and full-year revenue results, non-GAAP metrics such as adjusted EBITDA and adjusted loss per share, and commentary on revenue growth across open ablation, minimally invasive ablation, pain management, and appendage management product categories in the United States and international markets.
The news stream also highlights product and technology developments. Examples include the launch of the cryoXT ae device for post-operative pain management following amputation, expansion of the cryoICE ae platform, and first-in-human use of a dual energy platform that integrates Pulsed Field Ablation (PFA) with Advanced Radiofrequency Ablation (Advanced RFA) using the EnCompass ae clamp. These announcements provide insight into AtriCure’s product pipeline and its efforts to enhance surgical ablation efficiency and pain control.
Another key theme in AtriCure’s news is clinical research and trials. Updates on the LeAAPS trial and the BoxX-NoAF trial illustrate the company’s focus on generating evidence for Afib treatment, LAA exclusion, and reduction of new-onset post-operative Afib. In addition, AtriCure frequently announces participation in major healthcare and investor conferences, offering context on how management communicates its strategy and performance to the market.
By reviewing ATRC news on this page, readers can quickly see the latest disclosures on financial performance, regulatory and clinical milestones, and device launches that may influence perceptions of AtriCure’s business and its role in Afib and surgical pain management.
AtriCure, Inc. (NASDAQ: ATRC) has launched the EnCompass Clamp® as part of its Isolator Synergy™ Ablation System in the U.S. The clamp received FDA 510(k) clearance for cardiac tissue ablation during surgery, enhancing efficiency in concomitant ablation procedures. Key features include parallel closure, uniform pressure, and a magnetic guide for easier placement. CEO Michael Carrel highlighted its innovative design to improve surgical outcomes, while Dr. Prem Samuel praised its efficiency in minimizing tissue dissection and achieving effective results in a single maneuver.
AtriCure, a leader in surgical treatments for atrial fibrillation (Afib), announced its upcoming release of first-quarter financial results on May 3, 2022, at 4:30 PM ET. Investors can join a conference call or access a live audio webcast via the company's website. AtriCure's innovative technologies, including the FDA-approved Isolator® Synergy™ Ablation System and the widely used AtriClip® Left Atrial Appendage Exclusion System, support efficient Afib treatment, impacting millions globally. For more information, visit AtriCure.com.
AtriCure, Inc. (Nasdaq: ATRC) reported strong financial results for Q4 and full-year 2021. Q4 revenue reached $73.2 million, up 26.8% from 2020, driven by U.S. sales of key products. Full-year revenue was $274.3 million, a 32.8% increase. Gross profit for 2021 was $205.9 million, while the gross margin improved to 75%. However, the company faced a loss from operations of $12.5 million in Q4 and anticipates an adjusted EBITDA loss in 2022. The 2022 revenue forecast ranges from $315 million to $330 million, reflecting growth of 15% to 20%.
Summary not available.
AtriCure, a leader in surgical treatments for atrial fibrillation (Afib), will present at the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, at 8:40 a.m. Eastern Time. Interested parties can access the live audio webcast via the company's website. AtriCure offers innovative solutions for Afib, impacting over 33 million people globally. Their FDA-approved Isolator® Synergy™ Ablation System is a key technology, along with the widely used AtriClip® for left atrial appendage management.
AtriCure, a leader in surgical treatments for atrial fibrillation, announced it will release its fourth quarter and full year 2021 financial results on February 15, 2022. A conference call will follow at 4:30 p.m. ET the same day, accessible via phone or live audio webcast. AtriCure offers innovative technologies including the Isolator® Synergy™ Ablation System and AtriClip® products, which are widely used for managing Afib. With over 33 million people affected by Afib globally, AtriCure is committed to improving patient outcomes.
AtriCure, Inc. (NASDAQ: ATRC) reported preliminary financial results for Q4 and full year 2021, showing approximately $73.2 million in Q4 revenue, a 27% increase from 2020. Full-year revenue for 2021 is projected at $274.3 million, reflecting a 33% year-over-year growth. However, adjusted EBITDA showed a loss of $10 million, with an estimated loss per share of $1.20. Looking ahead, AtriCure projects 2022 revenue between $315 million and $330 million, indicating a 15-20% growth outlook amidst ongoing COVID-19 uncertainties.
AtriCure, Inc. (NASDAQ: ATRC), a leader in surgical treatments for atrial fibrillation (Afib), will participate in the 40th Annual J.P. Morgan Healthcare Conference. Management's presentation is scheduled for January 10, 2022, at 7:30 a.m. ET. Investors can access the live audio webcast through the company’s website. AtriCure specializes in innovative technologies for Afib management, including the FDA-approved Isolator® Synergy™ Ablation System, and widely used AtriClip® devices for left atrial appendage management. For more details, visit AtriCure.com.
AtriCure, a leader in surgical treatments for atrial fibrillation (Afib), announced its participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference. A prerecorded fireside chat is scheduled for November 22, 2021, accessible via the company's website. Additionally, management will hold investor meetings on December 1, 2021. AtriCure focuses on innovative technologies for Afib management, impacting over 33 million people globally, with notable products including the Isolator® Synergy™ Ablation System and AtriClip® Left Atrial Appendage Exclusion System.
AtriCure, a leader in atrial fibrillation treatments, reported strong Q3 2021 results with revenues of $70.5 million, a 28.7% increase year-over-year. U.S. revenue rose to $57.5 million due to stable cardiac procedures and high demand for Cryo Nerve Block and Hybrid AF therapy products. However, worldwide revenue fell by 1.3% from Q2 2021. Gross profit reached $52.2 million, with a gross margin of 74.1%. The company maintains its 2021 revenue guidance of $270-$275 million and adjusted EBITDA loss of approximately $10 million.